



# CHEMAPHOR

*A wellness company.*



## Investment Highlights

- Focus on multi-billion dollar companion animal and food animal markets
- A potential replacement to antibiotics where antibiotics are getting banned
- Preparing to launch Oximunol product in the US and other, international markets
- Strong IP to back up products into the 2020's



Pet Wellness



Optimize Livestock Health & Productivity



Human Health & Wellness

## Avivagen Animal Health

- Avivagen is a wholly-owned subsidiary of Chemaphor, to focus on marketing its animal health solutions
- Avivagen currently markets a natural, high-quality, once-a-day, chewable tablet for dogs:
  - Oximunol™ Chewable Tablets



- Chemaphor launched an interactive website in support of Avivagen's products and service ([www.avivagen.com](http://www.avivagen.com))

# Oximunol™

Chewable Tablets

### Market Potential

- Total market over \$1 billion

### Supports a Healthy Lifestyle

- Supports the overall health of the dog by improving hair coat, overall demeanor and mobility



### Commercial Status

- Launched in Canada
- Signed US distribution agreement with Teva Animal Health for Oximunol™ and future products
- Looking at international markets for future product distribution



## The Value of Our Products

Support body's own natural defense mechanisms.

**OxC-beta supports immune system — under challenge situations may:**

- Increase innate immune function leading to:
  - Earlier and enhanced detection of disease-causing microbes
  - Arrest of infections at early stage before they take hold
- Dampen inflammation, which may reduce unwanted damaging side-effects
- Optimize gastro-intestinal health, which may:
  - Favor good over bad bacteria in gut (probiotic-like effect)

## Chemaphor's Natural Advantage: OxC-beta

- A fully oxidized form of  $\beta$ -carotene, which is known for its apparent antioxidant/anti-aging benefits
- Proprietary, convenient, concentrated source of many carotenoid oxidation compounds with wide range of health benefits
  - Oximunol™ Chewables is OxC-beta specially formulated for companion animals
- OxC-beta has demonstrated benefits in:
  - Food animal growth & feed conversion efficiency
  - Supporting immune functions
  - Anti-cancer activity — e.g. prevention



## Leveraging OxC-beta in Additional Market Opportunities:

### Optimize Livestock Health & Productivity

#### Market Potential

- Global product launch over the next few years into a market currently worth USD\$4-\$5 billion

#### The OxC-beta Fit

- Enhanced immunity, early disease intervention, decreased mortality
  - Increased yield and decreased cost
- Non-antibiotic method of enhancing animal productivity and profitability
- In-feed and selected novel delivery forms



### Human Health & Wellness

#### Market Potential

- Functional food/natural supplement and skin and beauty markets are both more than US\$20 billion

#### The OxC-beta Fit

- Can be integrated into numerous nutritional supplements, functional foods, and skin care products

#### Development Status

- Initial target: topical skin application with early proof-of-concept study underway



## In the US, about 70% of antibiotics are used as growth promoters in livestock

***“FDA Urged to Make ‘Speedy Progress’ on Antibiotics”***

- Food Safety News, August 10 2011

***“World Coalition demands less Antibiotics on Farms”***

- Food Safety News, June 30 2011

***“South Korea Bans Antibiotics in Animal Feed”***

- Food Safety News, June 7 2011

## Chemaphor is developing a non-antibiotic, non-hormonal platform to replace antibiotics in food animals

### Leadership Team:

#### David Hankinson

Chief Executive Officer

Former CEO Solvay Pharma (Canada)

#### Dr. Graham Burton

President & Co-founder

Internationally known carotenoid and antioxidant scientist

#### Jacques Brault

Board Chairman

Businessman

#### Dr. Janusz Daroszewski

Chief Scientific Officer & Co-founder

Outstanding laboratory and manufacturing chemical expertise

#### Contact Information:

Please contact Chemaphor's financial advisors, Bloom Burton & Co., for further information.

#### Jolyon Burton

CEO & Head of Investment Banking

416-640-7585

[jbarton@bloomburton.com](mailto:jbarton@bloomburton.com)

tsx-v:cfr